Increased activin bioavailability enhances hepatic insulin sensitivity while inducing hepatic steatosis in male mice

Endocrinology

Volumn 154, Issue 6, 2013, Pages 2025-2033

  Ungerleider, Nathan A ^a   Bonomi, Lara M ^a   Brown, Melissa L ^a   Schneyer, Alan L ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ACTIVIN A; FOLLISTATIN; FOLLISTATIN 315 PROTEIN; FOLLISTATIN LIKE 3 PROTEIN; GLUCOSE; INSULIN; LIPID; PROTEIN KINASE B; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; BIOLOGICAL ACTIVITY; CELL STRAIN HEPG2; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FATTY LIVER; GENE EXPRESSION; GENE MUTATION; GLUCOSE TRANSPORT; HOMEOSTASIS; HUMAN; HUMAN CELL; INSULIN RESPONSE; INSULIN SENSITIVITY; LIPID ANALYSIS; LIPID METABOLISM; LIPID TRANSPORT; LIPOGENESIS; LIPOLYSIS; LIVER CELL; LIVER LEVEL; LIVER METABOLISM; MALE; MOUSE; NONHUMAN; NUTRIENT; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ACTIVINS; ANIMALS; BIOLOGICAL AVAILABILITY; CELLS, CULTURED; FATTY LIVER; GENE EXPRESSION; HEP G2 CELLS; HEPATOCYTES; HUMANS; IMMUNOBLOTTING; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); PHOSPHOLIPASES A2, CALCIUM-INDEPENDENT; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIGLYCERIDES;

EID: 84878436856     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1844     Document Type: Article

References (46)

1. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332(6037):1519-1523.
2. Li S, Brown MS, Goldstein JL. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci U S A. 2010;107(8):3441-3446.
3. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell. 2000;6(1):77- 86.
4. Matsumoto M, Han S, Kitamura T, Accili D. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest. 2006;116:2464-2472. (Pubitemid 44330145)
5. Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279:32345-32353. (Pubitemid 39014687)
6. 13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes. 1999;48(8):1600-1606.
7. Chakravarthy MV, Pan Z, Zhu Y, et al. "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab. 2005;1(5):309-322. (Pubitemid 43977168)
8. Stefan N, Häring HU. The metabolically benign and malignant fatty liver. Diabetes. 2011;60(8):2011-2017.
9. Bandsma RH, Prinsen BH, van Der Velden Mde S, et al. Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a. Pediatr Res. 2008;63(6):702-707.
10. Komatsu M, Yazaki M, Tanaka N, et al. Citrin deficiency as a cause of chronic liver disorder mimicking non-alcoholic fatty liver disease. J Hepatol. 2008;49(5):810-820.
11. Xia Y, Schneyer AL. The biology of activin: recent advances in structure, regulation and function. J Endocr. 2009;202:1-12.
12. Zaragosi LE, Wdziekonski B, Villageois P, et al. Activin A plays a critical role in proliferation and differentiation of human adipose progenitors. Diabetes. 2010;59:2513-2521.
13. Yndestad A, Haukeland JW, Dahl TB, et al. A complex role of activin A in non-alcoholic fatty liver disease. Am J Gastroenterol. 2009;104(9):2196-2205.
14. Magnusson B, Svensson PA, Carlsson LM, Sjöholm K. Activin B inhibits lipolysis in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2010;395(3):373-376.
15. Demeterco C, Beattie GM, Dib SA, Lopez AD, Hayek A. A role for activin A and betacellulin in human fetal pancreatic cell differentiation and growth. J Clin Endocrinol Metab. 2000;85:3892-3897.
16. Sidis Y, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, Schneyer A. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology. 2006;147(7):3586-3597. (Pubitemid 43901151)
17. Schneyer AL, Sidis Y, Gulati A, Sun JL, Keutmann H, Krasney PA. Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin. Endocrinology. 2008;149:4589-4595.
18. Matzuk MM, Lu N, Vogel H, Sellheyer K, Roop DR, Bradley A. Multiple defects and perinatal death in mice deficient in follistatin. Nature. 1995;374:360-363.
19. Kimura F, Sidis Y, Bonomi L, Xia Y, Schneyer A. The follistatin-288 isoform alone is sufficient for survival but not for normal fertility in mice. Endocrinology. 2010;151:1310-1319.
20. Mukherjee A, Sidis Y, Mahan A, et al. FSTL3 deletion reveals roles for TGF-β family ligands in glucose and fat homeostasis in adults. Proc Natl Acad Sci U S A. 2007;104:1348-1353. (Pubitemid 46184007)
21. Brown ML, Bonomi L, Ungerleider N, et al. Follistatin and follistatin like-3 differentially regulate adiposity and glucose homeostasis. Obesity (Silver Spring). 2011;19(10):1940-1949.
22. Li WC, Ralphs KL, Tosh D. Isolation and culture of adult mouse hepatocytes. Methods Mol Biol. 2010;633:185-196.
23. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226(1):497-509.
24. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7(2):85-96. (Pubitemid 43278292)
25. Loeffler B, Heeren J, Blaeser M, et al. Lipoprotein lipase-facilitated uptake of LDL is mediated by the LDL receptor. J Lipid Res. 2007;48(2):288-298. (Pubitemid 46220595)
26. Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown MS. Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem. 2002;277(11):9520-9528. (Pubitemid 34953041)
27. Bennett MK, Lopez JM, Sanchez HB, Osborne TF. Sterol regulation of fatty acid synthase promoter. Coordinate feedback regulation of two major lipid pathways. J Biol Chem. 1995;270(43):25578-25583.
28. Eberlé D, Hegarty B, Bossard P, Ferré P, Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004;86(11):839-848. (Pubitemid 39602764)
29. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461-1465.
30. Browning JD, Cohen JC, Hobbs HH. Patatin-like phospholipase domain-containing 3 and the pathogenesis and progression of pediatric nonalcoholic fatty liver disease. Hepatology. 2010;52(4):1189-1192.
31. Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2011;8(1):35-44.
32. Brown JM, Betters JL, Lord C, et al. CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance. J Lipid Res. 2010;51(11):3306-3315.
33. Koo SH, Dutcher AK, Towle HC. Glucose and insulin function through two distinct transcription factors to stimulate expression of lipogenic enzyme genes in liver. J Biol Chem. 2001;276(12):9437-9445.
34. Tortoriello DV, Sidis Y, Holtzman DA, Holmes WE, Schneyer AL. Human follistatin-related protein: a structural homologue of follistatin with nuclear localization. Endocrinology. 2001;142:3426-3434. (Pubitemid 32681749)
35. Sidis Y, Tortoriello DV, Holmes WE, Pan Y, Keutmann HT, Schneyer AL. Follistatin-related protein and follistatin differentially neutralize endogenous vs. exogenous activin. Endocrinology. 2002;143:1613-1624. (Pubitemid 34415875)
36. Huang Y, He S, Li JZ, et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A. 2010;107(17):7892-7897.
37. Welte MA. Proteins under new management: lipid droplets deliver. Trends Cell Biol. 2007;17(8):363-369. (Pubitemid 47375101)
38. He S, McPhaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010;285(9):6706-6715.
39. Chen W, Chang B, Li L, Chan L. Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology. 2010;52(3):1134-1142.
40. Basantani MK, Sitnick MT, Cai L, et al. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res. 2011;52(2):318-329.
41. Koncarevic A, Cornwall-Brady M, Pullen A, et al. A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health. Endocrinology. 2010;151:4289-4300.
42. Cadena SM, Tomkinson KN, Monnell TE, et al. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol. 2010;109:635-642.
43. Fournier B, Murray B, Gutzwiller S, et al. Blockade of the activin receptor IIb activates functional brown adipogenesis and thermogenesis by inducing mitochondrial oxidative metabolism. Mol Cell Biol. 2012;32(14):2871- 2879.
44. McPherron AC, Guo T, Wang Q, Portas J. Soluble activin receptor type IIB treatment does not cause fat loss in mice with diet-induced obesity. Diabetes Obes Metab. 2012;14(3):279-282.
45. Vamvini MT, Aronis KN, Chamberland JP, Mantzoros CS. Energy deprivation alters in a leptin- and cortisol-independent manner circulating levels of activin A and follistatin but not myostatin in healthy males. J Clin Endocrinol Metab. 2011;96(11):3416-3423.
46. Andersen GO, Ueland T, Knudsen EC, et al. Activin A levels are associated with abnormal glucose regulation in patients with myocardial infarction: potential counteracting effects of activin A on inflammation. Diabetes. 2011;60(5):1544-1551.